Sagimet Biosciences

Historical price data

Sagimet Biosciences is advancing a novel therapeutic platform centered on the selective inhibition of Fatty Acid Synthase (FASN), a key enzyme in the dysfunctional de novo lipogenesis pathway. The company's lead asset, denifanstat, has achieved critical milestones, including positive Phase 2b biopsy data in MASH (FASCINATE-2), Breakthrough Therapy designation from the FDA, and successful Phase 3 results in acne from a partner-led trial. With a seasoned leadership team and a clear path to Phase 3 in MASH, Sagimet's strategy is to develop first-in-class oral therapies for diseases driven by lipotoxicity, including MASH, acne, and select cancers.

Proprietary platform for developing selective, small-molecule inhibitors of Fatty Acid Synthase (FASN), the key enzyme in the de novo lipogenesis pathway, to treat diseases driven by overproduction of palmitate.